Interactive tool · Longevity testing

Longevity Test Cost Comparator

The biological-age and longevity-test market is a price-and-promise maze: an epigenetic clock, a glycan inflammation age, a broad blood panel and a multi-cancer screen are four entirely different products — yet they get pitched in the same breath. This tool lines up the options we've actually reviewed on current 2026 price, on what each one really measures, and on a blunt “what you get for the money” read. Filter by budget or test type.

Read before you use this

This is an educational price comparison, not medical advice and not a recommendation to buy any test. The products listed are screening and wellness tools, not diagnostics — a biological-age number won't diagnose disease, and the multi-cancer screen included here has no randomized trial showing it saves lives and can trigger a costly, sometimes-invasive workup over a false signal. None of these tests treats anything; they hand you data. Before spending money, talk to a licensed clinician about whether any of it is worth doing for your situation, and re-verify every price on the vendor's own page — direct-to-consumer pricing changes constantly.

Filter by test type

Filter by budget

Showing 5 of 5 tests

TruDiagnostic TruAge

Epigenetic clock

Current 2026 price

~$229 (low-to-mid hundreds)

One-time kit; retests sold separately

What it measures

DNA-methylation epigenetic age from a finger-stick blood spot on a high-density array, headlined by DunedinPACE — the best-validated pace-of-aging clock.

What you actually get for the money

The clock science is real and DunedinPACE is the most defensible output on the market. What the price implies but doesn't deliver: single-test noise can rival the change a short protocol would make, so it can't yet tell you whether your stack actually moved your aging.

Read our full TruDiagnostic TruAge review →

GlycanAge

Glycan (inflammation) age

Current 2026 price

~$199–$299 (mid hundreds)

One-time kit; periodic retests encouraged

What it measures

IgG glycosylation pattern from a finger-prick sample, returned as a 'glycan age' that tracks chronic low-grade inflammation (inflammaging).

What you actually get for the money

Measures a genuinely different axis — inflammatory aging, not methylation — and it's slower-moving, so a retest months later can plausibly reflect a real lifestyle shift. But it's a single inflammation-weighted index, not a whole-body age, and the evidence base is thinner than the epigenetic clocks.

Read our full GlycanAge review →

InsideTracker

Blood panel + DNA

Current 2026 price

~$249–$589 by tier (premium per marker)

One-time panels or annual subscription; optional DNA kit

What it measures

A blood panel (up to ~43 markers on the top tier) plus an optional DNA kit, an 'InnerAge' score, and a recommendation engine.

What you actually get for the money

The outcome-validated core — ApoB, hs-CRP, HbA1c, plus deficiency catches like ferritin and vitamin D — is real value. But you pay more per marker than broad panels, InnerAge is a proprietary blood composite (not a validated clock), and recommendations skew toward supplements it can sell.

Read our full InsideTracker review →

Function Health

Broad blood panel

Current 2026 price

~$499/yr (current market info)

Annual membership; one baseline + one retest

What it measures

A '100+ biomarker' baseline blood panel with a follow-up retest, a flag-against-optimal dashboard, and physician-ordered/reviewed labs.

What you actually get for the money

Buried in the long list are a few cheap, outcome-validated markers (ApoB, Lp(a), hs-CRP, HbA1c) most checkups skip — that's the real value. The rest is largely ordinary bloodwork dressed up by a big number, and it's structurally test-but-don't-treat: it flags problems it won't fix.

Read our full Function Health review →

Galleri (MCED)

Multi-cancer screen

Current 2026 price

~$949 (out of pocket; rarely insured)

One-time test; annual repeat suggested

What it measures

Reads tumor-shed cell-free DNA methylation to flag a cancer signal across many cancer types and predict the likely signal origin. This is a screening test, not a biological-age test.

What you actually get for the money

Real, peer-reviewed technology that roughly doubled cancers detected in a prospective study — but detection isn't survival: there's no randomized mortality trial, a 'no signal' result is not an all-clear, and a positive signal can trigger a costly, sometimes-invasive workup that ends in nothing found.

Read our full Galleri (MCED) review →

About these prices. Direct-to-consumer longevity-test pricing moves constantly, so every figure above is stated as a range reflecting current 2026 market positioning — not a fixed quote and not invented precision. Each one is anchored to the price our own published review for that product states as current market info. Always re-verify the live price on the vendor's own page before buying, and note that bundles, subscriptions, and retests change the real per-year cost.

Decide whether any of it is worth it

A price table only helps once you know what these numbers can and can't do. These go deeper on the science, the catches, and where testing sits in a real longevity plan:

This comparator is informational and not medical or financial advice. Prices are current-2026 market ranges that change frequently; verify them on each vendor's own page before purchasing. The tests compared are screening and wellness tools, not diagnostic instruments, and a biological-age estimate is not a measure of health or disease. Consult a licensed clinician before ordering any test or acting on a result, especially the multi-cancer screen.